xinlong Zang

Mr. xinlong Zang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
XZxinlong Zang
xinlong Zang
MCMingyang Cheng
Mingyang Cheng
XZXiaoxu Zhang
Xiaoxu Zhang
XCXuehong Chen
Xuehong Chen
Phytochemicals as dietary constituents are being widely explored for the prevention and treatment of various diseases. Quercetin, a major constituent of various dietary products, has attracted extensive interest due to its anti-proliferative capability, reversal of multidrug resistance, autophagy promotion and tumor microenvironment modulation on different cancer types. Although quercetin has shown potent medical value, its application as an antitumor drug is limited. Problems like poor solubility, bioavailability and stability, short half-life and weak tumor-targeting biodistribution make quercetin an unreliable candidate for cancer therapy. Nanoparticle based platforms have shown a number of advantages in delivering a hydrophobic drug like quercetin to diseased tissues. Quercetin nanoparticles have demonstrated high encapsulation efficiency, stability, sustained release, prolonged circulation time, improved accumulation at tumor sites and therapeutic efficiency. Moreover, a combination of quercetin with other diagnostic or therapeutic agents in one nanocarrier has achieved enhancements in detecting or treating tumors. In this review, we have tried to summarize the pharmacological activities of quercetin with regard to tumor cells and microenvironments in vitro and in vivo. Furthermore, various nanoformulations have been highlighted for quercetin delivery for cancer treatment. These results suggest that quercetin nanoparticles may be a promising antitumor therapeutic agent.

10 April 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XZxinlong Zang
xinlong Zang
XZXiaoxu Zhang
Xiaoxu Zhang
HHHaiyang Hu
Haiyang Hu
MQMingxi Qiao
Mingxi Qiao
XZXiuli Zhao
Xiuli Zhao
DCDa-Wei Chen
Da-Wei Chen

1 December 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
DZDeteng Zhang
Deteng Zhang
JSJinxiao Song
Jinxiao Song
ZJZhenghui Jing
Zhenghui Jing
HQHuan Qin
Huan Qin
YWYou Wu
You Wu
XZxinlong Zang
xinlong Zang
Background: Hepatocellular carcinoma (HCC) is a serious global health concern, accounting for about 90% of all liver cancer instances. Surgical treatment is a fundamental aspect of HCC management; however, the challenge of postoperative recurrence significantly impacts mortality rates. Methods: We have developed a pH and reactive oxygen species (ROS) dual stimulus-responsive drug delivery system (PN@GPB-PEG NPs) loaded with chemotherapeutic paclitaxel (PTX) and indoleamine 2.3-dioxygenase (IDO) inhibitor NLG919, for HCC chemoimmunotherapy. The physiochemical properties, such as particle size, zeta potential, morphology, and encapsulation efficiency, were characterized. Furthermore, we investigated in vitro cytotoxicity, cellular uptake and immunogenic cell death in tumor cells treated with our nanoparticles. In vivo biodistribution, antitumor effects and immune responses were assessed in an HCC mice model. Results: PN@GPB-PEG NPs display pH-responsive properties with improved targeting abilities toward tumors and improved uptake by HCC cells. Upon exposure to oxygen peroxide (H2O2), the sophisticated design allows for rapid release of therapeutic agents. In this process, PTX induces immunogenic cell death (ICD), which activates the immune system to generate an antitumor response. Simultaneously, NLG919 works to inhibit IDO, mitigating the immunosuppressive environment. This combination strategy leverages the advantages of both chemotherapy and immunotherapy, resulting in a powerful synergistic antitumor effect. In a mouse model of HCC, our nanoparticles effectively inhibited the growth of primary and recurrent tumors. Conclusion: These encouraging results highlight the potential of our nanocarrier system as an innovative therapeutic approach to address HCC primary tumor and postsurgical recurrence, providing hope for enhanced patient outcomes.

12 March 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XZxinlong Zang
xinlong Zang
XZXiaoxu Zhang
Xiaoxu Zhang
XZXiuli Zhao
Xiuli Zhao
HHHaiyang Hu
Haiyang Hu
MQMingxi Qiao
Mingxi Qiao
DCDa-Wei Chen
Da-Wei Chen

24 November 2020 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
XZxinlong Zang
xinlong Zang
JZJingyi Zhou
Jingyi Zhou
XZXiaoxu Zhang
Xiaoxu Zhang
YHYantao Han
Yantao Han
XCXuehong Chen
Xuehong Chen

8 July 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
XZxinlong Zang
xinlong Zang
JSJinxiao Song
Jinxiao Song
YLYanfeng Li
Yanfeng Li
YHYantao Han
Yantao Han